Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Operating Leases (2022 - 2026)

Kura Oncology has reported Operating Leases over the past 5 years, most recently at $13.2 million for Q1 2026.

  • Quarterly Operating Leases rose 68.08% to $13.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $13.2 million through Mar 2026, up 68.08% year-over-year, with the annual reading at $9.5 million for FY2025, 82.45% up from the prior year.
  • Operating Leases was $13.2 million for Q1 2026 at Kura Oncology, up from $9.5 million in the prior quarter.
  • Over five years, Operating Leases peaked at $13.2 million in Q1 2026 and troughed at $1.5 million in Q2 2023.
  • The 5-year median for Operating Leases is $6.3 million (2023), against an average of $6.3 million.
  • The largest YoY upside for Operating Leases was 301.58% in 2024 against a maximum downside of 18.42% in 2024.
  • A 5-year view of Operating Leases shows it stood at $2.5 million in 2022, then surged by 149.69% to $6.4 million in 2023, then dropped by 18.42% to $5.2 million in 2024, then skyrocketed by 82.45% to $9.5 million in 2025, then soared by 39.84% to $13.2 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Operating Leases are $13.2 million (Q1 2026), $9.5 million (Q4 2025), and $8.4 million (Q3 2025).